Stevanato Group S.p.A. (STVN)
Summary
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group S.p.A. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 125 | $1,718.75 | $2,495 | $776.25 | 45.16% |
 Point72 Asset Management LP Point72 Asset Management LP | 491,408 | $6.76M | $9.72M | $2.96M | 43.85% |
| MPM Mark P. Mennitt CenterBook Partners LP | 162,155 | $3.26M | $3.21M | -$52,700.38 | -1.62% |
| JDK James D. King Lindenwold Advisors Inc. | 8,780 | $214,495.4 | $173,800.1 | -$40,695.3 | -18.97% |
| EY Ellen York T. Rowe Price Investment Management Inc. | 3.22M | $48.04M | $63.24M | $15.21M | 31.65% |
Stevanato Group S.p.A. (STVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stevanato Group S.p.A. ever had a stock split?
Stevanato Group S.p.A. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Franco Stevanato CEO | NYSE Exchange | T9224W109 CUSIP |
| IT Country | 6,010 Employees | 11 Jun 2026 Last Dividend | - Last Split | 16 Jul 2021 IPO Date |
Overview
Stevanato Group S.p.A. is an influential entity specializing in the design, production, and distribution of a broad range of products and services tailored for the bio-pharma and healthcare industries. Established in 1949 and operating out of Piombino Dese, Italy, the company plays a pivotal role across various global markets including Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. Stevanato Group operates through two main business segments: Biopharmaceutical and Diagnostic Solutions; and Engineering. It stands as a key subsidiary of Stevanato Holding S.R.L., demonstrating a longstanding commitment to innovation and quality in the healthcare sector.
Products and Services
- Containment Solutions: These are designed to safely enclose pharmaceutical products, ensuring their integrity and protecting them from contamination.
- Drug Delivery Systems: Innovative systems that facilitate the administration of pharmaceuticals to patients, enhancing the effectiveness and user experience of medication therapies.
- Medical Devices: High-quality devices tailored for healthcare applications, contributing to diagnostics, treatment, and patient care.
- Diagnostic and Analytical Services: Services that support the healthcare industry by providing critical insights through diagnostics and advanced analytical technologies.
- Visual Inspection Machines: Sophisticated equipment designed for the inspection of pharmaceutical products, ensuring quality control and compliance with industry standards.
- Assembling and Packaging Machines: Machinery engineered for the efficient assembly and packaging of pharmaceuticals, ensuring product safety and streamlined manufacturing processes.
- Glass Forming Machines: Specialized equipment used in the manufacture of glass containers for pharmaceutical use, epitomizing precision and reliability.
